Louisville forum highlights barriers leaving Black patients underrepresented in lung cancer trials

A community forum in Louisville on Wednesday focused on why Black patients remain underrepresented in lung cancer clinical trials, bringing together health care professionals, community leaders, and advocates to discuss barriers that can limit participation in research programs. The event was held at the Muhammad Ali Center as part of ongoing efforts in the city to address health inequities tied to cancer outcomes.

Organizers said the discussion, framed around “Rhythms of Change: The Listening Lounge,” examined the gap between who receives care and who is able to enroll in clinical studies that can shape future treatments. Participants described lung cancer research participation as an issue that affects families across the community, not just patients currently being treated.

Forum attendees pointed to a range of factors that can interfere with trial enrollment, including differences in access to specialized medical services, challenges navigating complex trial processes, and concerns that can arise when patients do not feel informed, heard, or protected. Speakers also addressed the importance of communication between trial sites and communities, describing outreach and education as a practical step toward improving participation.

The forum took place in the Muhammad Ali Center, an institution with a mission centered on community dialogue and civic engagement. By convening clinicians and community stakeholders in a public setting, organizers aimed to create space for residents to raise concerns and for health care professionals to explain how trials work, what participation requires, and how potential risks and benefits are communicated.

Participants also discussed the role of local institutions in reducing barriers, including how clinics and researchers can improve connections with communities that have historically faced disparities in health outcomes. The event underscored that clinical trials depend on diverse enrollment so results can better reflect the populations that will ultimately rely on new therapies and guidance.

While the forum did not announce a single policy change during the event, it highlighted that trial participation is shaped by real-world conditions, including scheduling, transportation, referrals, and the ability to understand and complete enrollment steps. Organizers said improving representation in lung cancer trials requires sustained coordination between researchers, health care providers, and community organizations, not just one-time outreach.

The next phase, organizers said, is continuing engagement and follow-up conversations with residents and medical partners so concerns can be translated into concrete steps for outreach, education, and access. The issue raised in Louisville is expected to remain a focus for cancer research communities nationally, particularly as lung cancer continues to affect families in Kentucky and across the region.